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Abstract
The association between metabolic syndrome (MS) and bone health remains unclear. We
aimed to study the association between MS and hip bone geometry (HBG), femoral neck
bone mineral density (FN-BMD), and the risk of osteoporosis and incident fractures. Data of
2040 women and 1510 men participants in the third visit (1997–1999) of the Rotterdam
Study (RSI-3), a prospective population based cohort, were available (mean follow-up 6.7
years). MS was defined according to the recent harmonized definition. HBG parameters
were measured at the third round visit whereas FN-BMD was assessed at the third round
and 5 years later. Incident fractures were identified from medical registry data. After correct-
ing for age, body mass index (BMI), lifestyle factors and medication use, individuals with
MS had lower bone width (β = -0.054, P = 0.003), lower cortical buckling ratio (β = -0.81, P =
0.003) and lower odds of having osteoporosis (odds ratio =0.56, P = 0.007) in women but
not in men. Similarly, MS was associated with higher FN-BMD only in women (β = 0.028,
P=0.001). In the analyses of MS components, the glucose component (unrelated to diabe-
tes status) was positively associated with FN-BMD in both genders (β = 0.016, P = 0.01 for
women and β = 0.022, P = 0.004 for men). In men, waist circumference was inversely asso-
ciated with FN-BMD (β = -0.03, P = 0.004). No association was observed with fracture risk
in either sex. In conclusion, women with MS had higher FN-BMD independent of BMI. The
glucose component of MS was associated with high FN-BMD in both genders, highlighting
the need to preserve glycemic control to prevent skeletal complications.
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Introduction
Osteoporosis, a systemic skeletal disease, is an important public health problem due to its in-
creased risk for fractures, high morbidity and mortality and significant health care costs [1,2].
Different factors have been associated with osteoporosis including abdominal obesity, hyper-
tension, dyslipidemia and abnormal glucose metabolism, which are considered components of
metabolic syndrome. These components might affect bone differently. Obesity may lead to in-
creased bone mineral density (BMD) because it is associated with higher 17β-estradiol levels
and higher mechanical load, which may protect bone [3,4]. Visceral fat accumulation is associ-
ated with higher levels of pro-inflammatory cytokines, which may up-regulate receptor activa-
tors of nuclear kappa B ligand, leading to increased bone resorption and therefore decreased
BMD[5–7]. Also, although hyperglycemia is a predictor of osteoporotic fractures [8], the asso-
ciation between high glucose levels or insulin resistance with BMD is not well defined. For ex-
ample, diabetic individuals have higher BMD but increased risk of fractures [9–11]. Similarly,
the evidence for associations between dyslipidemia and hypertension with bone metabolism is
still inconclusive and the overall association between MS and bone health remains unclear [12–
15]. Two recent meta-analyses on the association between MS and BMD and fractures, were
not conclusive and whether metabolic syndrome might be associated with bone health beyond
the contribution of the individual components remains unclear [16,17]. Moreover, sex-differ-
ences have been suggested in this relationship, mainly due to differences in body fat distribu-
tion between men and women, but yet not clearly defined [18–20]. Recently, a new cluster of
criteria for diagnosis of MS had been presented with an emphasis on gender and ethnic differ-
ences in the measure of central obesity [21], which has not been adequately studied in relation
to bone.
We aimed to study the association between MS, femoral neck BMD (FN-BMD), hip bone
geometry (HBG), osteoporosis, and fractures among elderly Dutch men and women, partici-
pants of the Rotterdam Study and if these associations were independent of body mass index
(BMI). We examined whether MS was associated with FN-BMD and HBG parameters in fe-
males and males using a cross-sectional design and to determine whether MS predicts
FN-BMD, and incident fractures using a longitudinal design.
Materials and Methods
Study Population
The study was performed within the framework of the Rotterdam Study, a population-based
cohort among persons55 years and older living in the Ommoord district of Rotterdam, the
Netherlands. The rationale and design of the Rotterdam Study is described elsewhere [22]. The
study was approved by the Medical Ethical Committee of Erasmus University, and all partici-
pants gave informed consent. The present study used data from the baseline examination of
the third wave of the first cohort (RS-I-3) (1997–1999), in which 2,463 females and 1750 males
participated and FN-BMD was measured at the fourth round (RSI-4) (2002–2004).
Population for Analysis
Metabolic syndrome, FN-BMD, hip bone geometry and osteoporosis. Among 2463 fe-
males and 1750 males, 402 women and 231 men did not have fasting samples or measures
of at least on component of MS, and were therefore excluded from the analysis. Furthermore,
FN-BMD at RSI-3 (1997–1999), was not assessed in 534 females and 353 males, leaving 1527 fe-
males and 1166 males for the cross-sectional analysis regarding MS, FN-BMD and osteoporosis.
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For the analysis concerning MS and HBG, 124 female and 48 males were further excluded be-
cause of no-available information on HBG data (S1 and S2 Figs).
Metabolic syndrome and fractures risk. Among 2061 females and 1519 males with infor-
mation available on MS components at RSI-3, 29 subjects (21 females and 9 males) were ex-
cluded because there was no data on fracture follow-up, hence leaving 2040 females and 1510
males for the analysis on MS and fracture risk. Furthermore, for each type of fracture, prevalent
cases were excluded from the analysis (S1 and S2 Figs).
Metabolic Syndrome Definition
MS was defined according to the new criteria announced by a joint scientific statement from
the International Diabetes Federation (IDF), the American Heart Association/National Heart,
Lung, and Blood Institute (AHA/NHLBI), World Heart Federation, International Atheroscle-
rosis Society and International Association for the Study of Obesity [21]. Participants with
three or more of the following components were classified as having MS: (1) abdominal obesity
(waist circumference (WC)102 cm for men or88 cm for women); (2) high triglycerides
(TG) (150 mg/dL) (3) low HDL (40 mg/dL for men or50 mg/dL for women) (4) elevated
blood pressure (BP) (systolic BP130 and/or diastolic BP85 mmHg) or (5) high glucose
(fasting glucose level100 mg/dL). The criteria for abdominal obesity were adopted from the
cutoffs for European people region [21].
Skeletal Assessments
All events, including incident fractures and death, were reported by general practitioners (GPs) in
the research area by means of a computerized system. All reported events were verified by two
trained research physicians, who independently reviewed and coded the information. Subsequently,
all coded events were reviewed by a medical expert for final classification. Subjects were followed
from their baseline visit until January 1, 2007 or until a first fracture or death occurred. FN-BMD
(g/cm2) at the RS1-3 (1997–1999) was measured by Dual-energy X-ray absorptiometry (DXA)
using a Lunar DPX-L densitometer [23](Lunar Radiation Corp., Madison, WI, USA) and analyzed
with DPX-IQ v.4.7d software whereas at the RS1-4 (2002–2004), FN-BMDwas measured using a
GE Lunar Prodigy bone densitometer. No cross-calibration between the twomeasures was per-
formed. From the FN-BMD, sex-specific T-scores were calculated using the NHANES reference
population [24]. Peak bone mass, as converted to the corresponding Lunar value, was 1.04 ± 0.14
g/cm2 for women and 1.13 ± 0.16 g/cm2 for men. Osteoporosis was defined as a T-score below -2.5
SD whereas osteopenia as a T-score between -1.0 and -2.5. Hip structural analysis [25] was used to
measure HBG from the DXA scans of the femur narrow neck region as described previously [26].
Assessment of Covariates
At the third visit, smoking habits were coded as current, and former/never. BMI was calculated as
weight (in kg)/height (in m2). Information on medication use at the third round visit included the
use of diuretics, hormonal replacement therapy, systemic corticosteroids, drugs for bone and other
musculoskeletal diseases. A faller was defined as an individual with a history of one, two, or more
falls without precipitating trauma (e.g., car accident or sport injury) in the 12 months preceding the
interview at the third round visit. Falling frequency was then recorded as never or at least one. At
the third visit to the research center, the total weekly duration of physical activity was assessed by
an adapted version of the Zutphen Physical Activity Questionnaire and the LASA Physical Activity
Questionnaire. The Dutch Healthy Diet (DHD)-index assessed at the first wave of the Rotterdam
Study (1989–1993), was used to take into account overall dietary quality. The DHD represents
compliance to the Dutch Guidelines for a Healthy Diet as assessed from the FFQ at baseline [27].
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Statistical Analysis
Continuous variables were reported as mean ± SD unless stated otherwise and categorical vari-
ables were presented as percentages. Linear regression models and logistic regression were used
to determine the cross-sectional association between MS and the number of MS components
with FN-BMD, HBG parameters and osteoporosis. For the longitudinal association of MS and
its components with FN-BMD, linear regression models were fitted in generalized estimated
equations (GEE) with exchangeable correlation structure adjusting for the within-subject cor-
relations due to the repeated measurements of FN-BMD in the same individual (partial Pear-
son correlation = 0.93 and intra-class correlation = 0.96) [28]. Risk of incident fractures was
evaluated for the association with MS and the number of different MS components using Cox
proportional hazard regression models. The proportional hazard assumption of the Cox model
was checked by the visual inspection of log minus log plots and by performing an interaction
test with time. Models for fracture, FN-BMD, and hip geometry were corrected for potential
confounders, including age, height, smoking status, physical activity, alcohol intake, fallings in
the last 12 months, use of diuretics drugs, use of hormone replacement therapy, use of cortico-
steroids drugs, use of drugs for bone and other musculoskeletal diseases and Dutch Healthy
Diet Index; cross-sectional FN-BMD and HBG were additionally adjusted for BMI and weight
respectively, longitudinal analysis on FN-BMD were additionally adjusted for BMI and the two
time points FN-BMDmeasurements were performed (index time) (to adjust also for the lack
of cross-calibration between the two measures of BMD) and the interaction between MS (or
MS component) and the index time whereas fracture analysis were further adjusted for weight.
To analyze the relationship between individual features of MS and FN-BMD, GEE was per-
formed after adjusting for the possible covariates described above with respect to the presence
of each component. All analyses were conducted separately for men and women because of
gender differences in MS and bone parameters (also the formal tests of interaction (sex×MS) in
BMI adjusted models were statistically significant). To correct for multiple testing, a two-tailed
P value of 0.025 or less was considered as statistically significant.
To examine if diabetic individuals could influence the associations, we re-ran all analyses ex-
cluding subjects with MS who had diabetes mellitus at the third round visit. To adjust for po-
tential bias associated with missing data we used multiple imputation procedure (N = 5
imputations). Rubin’s method was used for the pooled regression coefficients (β) and 95%
Confidence Intervals. All analyses were performed using SPSS statistical software (SPSS, ver-
sion 21.0; SPSS Inc, Chicago, Illinois).
Results
The baseline characteristics of the study population included in the analysis of MS with
FN-BMD are shown in Table 1. Six hundred ninety eight (45.7%) female and 435 (37.3%) male
participants had MS. On average, female participants were older than men (72.38 vs. 72.04)
and were more likely to have osteoporosis (18.2% vs. 14.8%). Anthropometric, lifestyle and
other characteristics of the excluded participants did not substantially differ from the partici-
pants included in the study (data not shown).
Cross-sectional association between Metabolic Syndrome, FN-BMD,
Hip Bone Geometry and Osteoporosis
In females, in age-adjusted models, MS was associated with higher FN-BMD (β = 0.056, P = 4.5
10−17), higher cortical thickness (β = 0.01, P = 6.2 10−07), higher section modulus (β = 0.053,
P = 0.001), lower cortical buckling ratio (β = -1.93, P = 2.2 10−11) whereas no association was
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PLOS ONE | DOI:10.1371/journal.pone.0129116 June 12, 2015 4 / 15
found with bone width (β = -0.033, P = 0.055) (Table 2). After additional adjustments for con-
founding by BMI, height, lifestyle factors and medication use, the associations were attenuated
or reversed (Table 2); however MS was still positively associated with FN-BMD (β = 0.017,
P = 0.010), bone width (β = -0.054, P = 0.003) and cortical buckling ratio (β = -0.81, P = 0.003)
(Table 2). Similarly, in the multivariable models, the number of MS components was positively
associated with FN-BMD (β = 0.006,P = 0.012), femoral neck width (β = -0.026, P<0.001) and
cortical buckling ratio (β = -0.26, P = 0.011) whereas no association was observed between MS
and cortical thickness or section modulus in females (P>0.025) (Table 2). Also, MS and the
number of its components, were inversely associated with osteopenia and osteoporosis in age-
adjusted models (osteopenia: OR = 0.65, P = 3.2 10−04, Pfor no. of MS components<0.0001; osteopo-
rosis: OR = 0.23, P = 3.3 10−16, Pfor no. of MS components<0.0001) (Fig 1). After adjustment for
BMI although attenuated, the inverse association between MS and osteoporosis remained sig-
nificant (OR = 0.56, P = 0.006) (Fig 1). Also, a positive association was observed between the
number of MS features and osteoporosis in the multivariable model Pfor no. of MS components =
0.03) (Fig 1). Additional adjustment for other confounders did not affect the results (data not
shown). In males, MS was associated with higher FN-BMD (β = 0.031, P = 7.4 10−05), higher
cortical thickness (β = 0.009, P = 9.3 10−07), higher section modulus (β = 0.096, P = 3.0 10−07)
and lower cortical buckling ratio (β = -0.88, P = 2.2 10−04) in age-adjusted models (Table 2).
However, after adjustment for BMI and height, MS was neither statistically significantly
Table 1. Baseline characteristics for participants.
Women (N = 1,527) Men (N = 1,166)
Age 72.38 ±6.81 72.04 ±6,51
Metabolic Syndrome (n, %) 698 (45.7) 435 (37,3)
Bone mineral density, 1st round (g/cm2) 0.82 ± 0.14 0.93 ± 0.14
Bone mineral density, 2nd round (g/cm2)* 0.82 ± 0.13 0.92 ± 0.13
Cortical thickness (cm)** 0.13 ± 0.04 0.15 ± 0.03
Bone width (cm)** 2.93 ± 0.32 3.37 ± 0.30
Section modulus (cm3)** 0.97 ± 0.31 1.41 ± 0.34
Cortical buckling ratio** 13.50 ± 5.00 13.15 ± 3.96
Osteoporosis (n, %) 278 (18.2) 172 (14.8)
Osteopenia (n, %) 855 (56.0) 640 (54.6)
Diabetes Mellitus (n,%) 194 (12.7) 172 (14.8)
BMI (kg/m2) 27.15 ±4.25 26.35 ±3.19
Smoking (Yes) (n,%) 216 (14.0) 201 (17.2)
Physical activity (min/week) 2820.62 ±1103.74 2519.15 ±1178
Alcohol intake (g/day) 1,57 (396821.4) 4.29 (79364.3)
Dutch Healthy Diet-Index 50.84 ±9.92 45.55 ±9.78
Fallings in the last 12 months (n, %) 415 (27.2) 225 (19.3)
Diuretic drugs (n,%) 264 (17.3) 163 (14.0)
HRT (n,%) 66 (4.3) 3 (0.26)
Corticosteroid drugs (n,%) 51 (3.3) 25 (2.1)
Bone drugs (n,%) 56 (3.86) 6 (0.53)
Other musculoskeletal drugs (n,%) 32 (2.1) 6 (0.53)
HRT: Hormone replacement therapy
*999 female and 768 male individuals with available measure of BMD at the second round
**1,403 female and 1,118 male individuals with available measure of hip bone geometry
doi:10.1371/journal.pone.0129116.t001
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Table 2. The cross-sectional association of metabolic syndromewith bonemineral density and bone geometry.
Women Men
FN-BMD, n = 1,527 FN-BMD, n = 1,166
Metabolic Syndrome β (95%CI) P-value Metabolic Syndrome β (95%CI) P-value
Model 1 0.056 (0.043; 0.069) 4.5 10−17 Model 1 0.031 (0.015; 0.047) 7.4 10−5
Model 2 0.018 (0.003; 0.030) 0.007 Model 2 -0.005 (-0.014; 0.003) 0.55
Model 3 0.017 (0.004; 0.030) 0.10 Model 3 -0.002 (-0.020; 0.015) 0.82
No. of MS components No. of MS components
Model 1 0.022 (0.017; 0.026) 8.08 10−20 Model 1 0.012 (0.006; 0.018) 9.6 10−5
Model 2 0.007 (0.002;0.011) 0.009 Model 2 -0.004 (-0.007; 0.001) 0.30
Model 3 0.006 (0.001; 0.011) 0.012 Model 3 -0.002 (-0.009; 0.005) 0.53
Cortical thickness, n = 1,403 Cortical thickness, n = 1,118
Metabolic Syndrome β (95%CI) P-value Metabolic Syndrome β (95%CI) P-value
Model 1 0.010 (0.005; 0.014) 6.2 10−7 Model 1 0.009 (0.005; 0.012) 9.3 10−7
Model 2 0.001 (-0.003; 0.005) 0.69 Model 2 -0.001 (-0.003; 0.001) 0.56
Model 3 0.001 (-0.004; 0.006) 0.73 Model 3 -0.0005 (-0.004; 0.003) 0.80
No. of MS components No. of MS components
Model 1 0.004 (0.003; 0.006) 1.33 10−8 Model 1 0.003 (0.002; 0.005) 7.3 10−7
Model 2 0.001 (-0.001; 0.002) 0.42 Model 2 -0.001 (-0.002; 0.000) 0.26
Model 3 0.001 (-0.001; 0.002) 0.49 Model 3 -0.001 (-0.002; 0.001) 0.45
Bone width, n = 1,403 Bone width, n = 1,118
Metabolic Syndrome β (95%CI) P-value Metabolic Syndrome β (95%CI) P-value
Model 1 -0.033 (-0.068; 0.001) 0.055 Model 1 0.006 (-0.003; 0.042) 0.76
Model 2 -0.051 (-0.09; -0.015) 0.005 Model 2 -0.030 (-0.068; 0.008) 0.12
Model 3 -0.054 (-0.091; -0.018) 0.003 Model 3 -0.029 (-0.068; 0.010) 0.14
No. of MS components No. of MS components
Model 1 -0.015 (-0.027; -0.002) 0.021 Model 1 0.001 (-0.014; 0.015) 0.93
Model 2 -0.025 (-0.038; -0.011) 0.0003 Model 2 -0.014 (-0.029; 0.001) 0.076
Model 3 -0.026 (-0.039; -0.012) 0.0002 Model 3 -0.013 (-0.029; 0.002) 0.097
Section Modulus, n = 1,403 Section Modulus, n = 1,118
Metabolic Syndrome β (95%CI) P-value Metabolic Syndrome β (95%CI) P-value
Model 1 0.053 (0.021; 0.086) 0.001 Model 1 0.096 (0.056; 0.136) 3.0 10−7
Model 2 -0.029 (-0.062; 0.003) 0.08 Model 2 -0.028 (-0.068; 0.011) 0.159
Model 3 -0.03 (-0.063; 0.003) 0.078 Model 3 -0.021 (-0.061; 0.019) 0.30
No. of MS components No. of MS components
Model 1 0.024 (0.012; 0.036) 5.6 10−5 Model 1 0.036 (0.021; 0.052) 5.0 10−7
Model 2 -0.011 (-0.023; 0.002) 0.09 Model 2 -0.017 (-0.032; -0.001) 0.036
Model 3 -0.011 (-0.023; 0.001) 0.08 Model 3 -0.014 (-0.030; 0.002) 0.094
Cortical Buckling Ratio, n = 1,403 Cortical Buckling Ratio, n = 1,118
Metabolic Syndrome β (95%CI) P-value Metabolic Syndrome β (95%CI) P-value
Model 1 -1.93 (-2.42; -1.43) 2.2 10−11 Model 1 -0.88 (-1.35; -0.41) 2.2 10−4
Model 2 -0.79 (-1.32; -0.26) 0.004 Model 2 0.036 (-0.23; 03037) 0.89
Model 3 -0.81 (-1.34; -0.27) 0.003 Model 3 -0.049 (-0.56; 0.46) 0.85
No. of MS components No. of MS components
Model 1 -0.71 (-0.89; -0.53) 3.1 10−12 Model 1 -0.314 (-0.50; -0.13) 0.001
Model 2 -0.25 (-0.45; -0.06) 0.012 Model 2 0.101 (-0.003; 0.21) 0.33
(Continued)
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associated with FN-BMD nor with hip bone geometry parameters (Table 2). Similarly, there
was no association between number of MS components, FN-BMD and hip bone geometry in
the fully adjusted models (Table 2). Also, in age-adjusted models, MS was inversely associated
with osteoporosis but not with osteopenia (osteopenia: OR = 0.77, P = 0.056, Pfor no. of MS
components = 0.008; osteoporosis: OR = 0.49, P = 0.001, Pfor no. of MS components = 0.002) (Fig 1).
However, no association was observed between MS and its components with osteopenia or os-
teoporosis after adjustment for BMI (Fig 1) and other confounders (data not shown).
Longitudinal Association between Metabolic Syndrome and FN-BMD
Similar to the cross-sectional analysis, MS and the number of its features was positively associ-
ated with FN-BMD (β = 0.028, P = 0.001; Pfor no. of MS components = 0.001) in the multivariable
model in females, which tended to go away across time (interaction MS x index time: β =
-0.008, p = 0.031; interaction MS component x index time: β = -0.003, p = 0.021). No associa-
tion was observed between MS or its features and adjusted FN-BMD in males (Table 3).
Association between Metabolic Syndrome and Fracture Risk
In females, no association was observed between MS and any type of fractures, neither in age
and gender adjusted model, nor in the multivariable model (HR = 0.91: 95%CI: 0.73–1.15)
(Table 4). Also no association was observed for non-vertebral fractures (HR = 0.94: 95%CI:
0.73–1.21) or vertebral fractures (HR = 0.83: 95%CI: 0.56–1.24) (Table 3). Similarly, there was
no significant association between MS with any type of fractures or with subtypes of fractures
in males (Table 4). Nevertheless, in males, significant inverse associations were observed be-
tween numbers of MS components with any type of fractures (P = 0.015) and with non-verte-
bral fractures (P = 0.017) (Table 3).
Additional Analysis
S1 Table shows the effect of individual components of MS on the adjusted FN-BMD. In both
genders, elevated glucose levels were associated with higher BMD (in females: β = 0.016,
P = 0.01; in males: β = 0.022, P = 0.004). In women, but not in men, HDL-cholesterol was posi-
tively associated with FN-BMD (β = 0.013, P = 0.01). In men but not in women, waist circum-
ference component was inversely associated with FN-BMD (in males: β = -0.030, P = 0.004).
No association was observed between other components of MS and adjusted FN-BMD in
either gender.
Exclusion of subjects with MS having diabetes mellitus (194 females and 172 males) did not
substantially change any of the results (data not shown). Moreover, substitution in the
Table 2. (Continued)
Women Men
Model 3 -0.26 (-0.46; -0.06) 0.011 Model 3 0.07 (-0.14; 0.27) 0.51
MS, metabolic syndrome; FN-BMD, femoral neck bone mineral density
Model 1: Adjusted for age
Model 2: Model 1 +body mass index and height for FN-BMD and weight + height for hip bone geometry parameters.
Model 3: Model 2 + smoking status, physical activity, alcohol intake, fallings in the last 12 months, use of diuretics drugs, use of hormone replacement
therapy, use of corticosteroids drugs, use of drugs for bone and other musculoskeletal diseases and Dutch Healthy Diet Index.
doi:10.1371/journal.pone.0129116.t002
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multivariable models of BMI with weight and vice versa, did not change any of the results (data
not shown).
Discussion
To our knowledge, this is the first study to simultaneously examine the association between
metabolic syndrome, FN-BMD, HBG parameters, osteoporosis and fracture risk by using the
most recent definition of MS. Females with MS, have significantly higher BMD, narrower bone
at the hip, and increased bone instability (lower buckling ratio), lower odds of having osteopo-
rosis than non-MS individuals, independent of BMI. In males, the positive association of MS
Fig 1. The association betweenmetabolic syndrome, osteopenia and osteoporosis in women andmen.Reference group are subjects with no
osteopenia, neither osteoporosis: Confounders include age, body mass index, height, smoking status, physical activity, alcohol intake, fallings in the last 12
months, use of diuretics drugs, use of hormone replacement therapy, use of corticosteroids drugs, use of drugs for bone and other musculoskeletal diseases
and Dutch Healthy Diet Index.
doi:10.1371/journal.pone.0129116.g001
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with BMD and HBG geometry was explained by BMI. Our results on fracture risk, suggest no
consistent influence of MS in either gender.
According to the observational data in the past decade, the relationship between MS and its
components, BMD and fracture risk is controversial. In line with our findings, a recent meta-
analysis showed that MS may have beneficial influence on BMD in Caucasian individuals [16].
Also, another meta-analysis on MS and fracture risk, concluded that individuals with MS are
not at higher risk of having fractures [17]. MS is a cluster of conditions, interacting with each
other, and therefore the mechanism behind the effect of MS on BMD and fractures risk is com-
plicated and has not yet been investigated in detail. Although, the association between individ-
ual components of MS and bone metabolism have been extensively studied, the results are yet
inconclusive. (1) For example, central obesity has been associated with higher BMD in some
studies, but some others and our study as well have shown detrimental effects[29,30]. Also,
obesity, is a risk factor for fractures of the humerus and ankle, but protects against fractures of
hip and vertebral bodies [31–33]. (2) Elevated glucose levels have been linked to better, worse
or similar bone outcomes [18,34,35]. (3) Hypertension is postulated to be associated with low
bone mass due to urinary calcium excretion and therefore increase fracture risk [36], but, con-
trary to common belief, intensive antihypertensive treatment was not associated with an in-
creased risk of falls or non-spine fractures in patients with type 2 diabetes in the Action to
Control Cardiovascular Risk in Diabetes (ACCORD) randomized trial [37]. Hypertriglyceride-
mia contributes to a lower risk of fractures, which may partly be explained by the interaction
with protein matrix and bone minerals [12,38]. However, Kim et al [39] and Adami et al [13]
found that high triglyceride levels and low HDL-cholesterol were negatively associated with
BMD. Therefore, as observed in the current study, the combined effects of these components
on bone metabolism may be beneficial or insignificant.
The positive association between MS and BMD observed in the present study was mainly
driven by glucose levels. MS is a risk factor for type 2 diabetes mellitus which has been associat-
ed with an increase in fracture risk. In contrast to MS individuals, evaluation of BMDmay not
Table 3. The longitudinal association of metabolic syndromewith bonemineral density.
Women (N = 1,527) Men (N = 1,166)#
Metabolic syndrome (Yes vs. No) FN-BMD P-value Metabolic syndrome (Yes vs. No) FN-BMD P-value
Model 1: β, 95% CI 0.063 (0.048; 0.079) 2.44 10−15 Model 1: β, 95% CI 0.031 (0.015; 0.047) 0.0001
Model 2: β, 95% CI 0.028 (0.015; 0.042) 0.001 Model 2: β, 95% CI -0.006 (-0.016; 0.004) 0.58
Model 3: β, 95% CI 0.028 (0.012; 0.043)* 0.001 Model 3: β, 95% CI -0.002 (-0.022; 0.017) 0.83
No. of MS components (continuous) No. of MS components (continuous)
Model 1: β, 95% CI 0.025 (0.019; 0.030) 5.4 10−20 Model 1: β, 95% CI 0.013 (0.006; 0.020) 0.0003
Model 2: β, 95% CI 0.011 (0.005;0.016) 0.0004 Model 2: β, 95% CI -0.003 (-0.007; 0.001) 0.46
Model 3: β, 95% CI 0.010 (0.004; 0.016)** 0.001 Model 3: β, 95% CI -0.001 (-0.009; 0.006) 0.75
MS, metabolic syndrome; FN-BMD, femoral neck bone mineral density
Model 1: Adjusted for age and type of DXA scan
Model 2: Model 1 +body mass index and height
Model 3: Model 2 + smoking status, physical activity, alcohol intake, fallings in the last 12 months, use of diuretics drugs, use of hormone replacement
therapy, use of corticosteroids drugs, use of drugs for bone and other musculoskeletal diseases and Dutch Healthy Diet Index.
*index time (time points when the DXA measurements were performed), β = -0.012, p<0.001; interaction MS x index time: β = -0.008, p = 0.031
** index time, β = -0.012, p<0.001; interaction MS component x index time: β = -0.003, p = 0.021
#no signiﬁcant interaction between MS (or MS component) and index time (p>0.50) was observed in any of the analysis in men and therefore data are
not shown
doi:10.1371/journal.pone.0129116.t003
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be adequate for predicting fracture risk in patients with type 2 diabetes, who are unlikely to be
diagnosed with osteoporosis and increased risk of fracture [10]. In the large Rotterdam Study,
we previously showed that, similar to MS individuals, diabetic patients have higher BMD and
stronger bone geometry, which would protect them against fractures [10]. However, in contrast
to MS individuals, diabetic individuals have an increased fracture risk, which was shown to be
driven by poor glycemic control [10]. We postulate that increased bone fragility may be caused
by chronically elevated glucose levels, which may lead to accumulation of microcracks and/or
cortical porosity. MS is a health condition which predisposes to type 2 diabetes mellitus, but
may not yet be characterized by chronically elevated glucose levels. In the present study, the
positive association between MS and BMD persisted also after exclusion of subjects with MS
who had diabetes mellitus. Thus, it is likely that, microcracks and/or cortical porosity may not
be present in MS individuals which may explain why MS subjects do not yet experience a high
Table 4. Metabolic syndrome and fracture risk.
Women Men
All Fractures (371) All Fractures (147)
Metabolic Syndrome Hazard ratio (95%CI) P-value Metabolic Syndrome Hazard ratio (95%CI) P-value
Model 1 0.85 (0.69–1.04) 0.12 Model 1 0.85 (0.60–1.20) 0.36
Model 2 0.91 (0.72–1.14) 0.40 Model 2 0.74 (0.69–1.08) 0.12
Model 3 0.91 (0.73–1.15) 0.43 Model 3 0.68 (0.46–1.006) 0.054
No. of MS components No. of MS components
Model 1 0.94 (0.87–1.02) 0.11 Model 1 0.92 (0.81–1.06) 0.24
Model 2 0.97 (0.89–1.05) 0.44 Model 2 0.86 (0.74–1.001) 0.055
Model 3 0.97 (0.89–1.06) 0.47 Model 3 0.82 (0.70–0.9964) 0.015
Non-Vertebral Fractures (307) Non-Vertebral Fractures (102)
Metabolic Syndrome Hazard ratio (95%CI) P-value Metabolic Syndrome Hazard ratio (95%CI) P-value
Model 1 0.90 (0.72–1.13) 0.36 Model 1 0.89 (0.59–1.35) 0.59
Model 2 0.94 (0.73–1.21) 0.63 Model 2 0.69 (0.55–1.88) 0.12
Model 3 0.94 (0.73–1.21) 0.61 Model 3 0.64 (0.40–1.03) 0.068
No. of MS components No. of MS components
Model 1 0.96 (0.89–1.05) 0.38 Model 1 0.94 (0.79–1.10) 0.42
Model 2 0.98 (0.89–1.08) 0.70 Model 2 0.83 (0.68–1.01) 0.047
Model 3 0.98 (0.89–1.08) 0.66 Model 3 0.75 (0.66–0.96) 0.017
Vertebral Fractures (123) Vertebral Fractures (62)
Metabolic Syndrome Hazard ratio (95%CI) P-value Metabolic Syndrome Hazard ratio (95%CI) P-value
Model 1 0.68 (0.47–0.98) 0.039 Model 1 0.65 (0.37–1.13) 0.13
Model 2 0.80 (0.53–1.19) 0.27 Model 2 0.67 (0.49–1.25) 0.20
Model 3 0.83 (0.56–1.24) 0.36 Model 3 0.60 (0.32–1.14) 0.12
No. of MS components No. of MS components
Model 1 0.84 (0.73–0.96) 0.01 Model 1 0.84 (0.6–1.03) 0.10
Model 2 0.86 (0.76–1.03) 0.11 Model 2 0.85 (0.75–1.07) 0.17
Model 3 0.90 (0.77–1.05) 0.18 Model 3 0.81 (0.64–1.03) 0.09
“( )”, number of fractures
Model 1: Adjusted for age
Model 2: Model 1 +Height and Weight
Model 3: Model 2 + smoking status, physical activity, alcohol intake, fallings in the last 12 months, use of diuretics drugs, use of hormone replacement
therapy, use of corticosteroids drugs, use of drugs for bone and other musculoskeletal diseases and Dutch Healthy Diet Index.
doi:10.1371/journal.pone.0129116.t004
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risk of fractures (Fig 2). Follow-up studies focusing on the health life trend of MS individuals in
relation to bone are thus needed.
The current study shows that no gender differences are observed between MS and unadjust-
ed BMD and fracture risk, but that gender differences become prominent after adjustment for
BMI and that in men, the observed positive association between MS and BMD and hip bone
geometry parameters is explained by obesity. Similar to our observations, the meta-analysis in-
vestigating the association between MS and unadjusted BMD concluded that there were no
gender differences [16]. Also, the recent meta-analysis examining the association between MS
and fracture risk did not observed any difference between men and women with similar esti-
mates to our study [17]. In contrast, gender differences in the association between MS and
BMI-adjusted BMD have been previously described, showing less beneficial effects of MS on
Fig 2. Level of glycemic derangement, bone architecture and fracture risk. Cartoon depicting the differences in bone mineral density, fracture risk and
changes in bone microarchitecture across the stages of glucose derangement. Metabolic syndrome and diabetes mellitus individuals have higher BMD but
do not experience yet an increase in fracture risk. With sustained bad glycemic control, the damage of bone microarchitecture represented by accumulation
of microcracks and cortical porosity becomes a possibility which may explain the bone fragility and fracture susceptibility despite the observed increase in
BMD. Drawing is not to scale.
doi:10.1371/journal.pone.0129116.g002
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bone health in men than in women [39,40]. In contrast to our results, both studies observed a
decrease in FN-BMD with increasing number of MS components in men, but not in women.
However, both studies were characterized by other ethnicities or were performed in a younger
population. It has been shown that the association between MS and BMD differs by ethnicity
[16]. Also, BMD declines by age and this decline differs by gender [41]. In a twin study, fat
mass and body fat distribution seem to have different relationships with BMD according to
gender and age [42]. Since fat deposition differs according to gender, it has been hypothesized
that mechanical effect and estrogen synthesis predominate in women, while bone-deleterious
effects of fat, related to oxidative stress and chronic inflammation, predominate in men [43].
Therefore, bone mass in males with MS may be more influenced by visceral fat than in women
which may explain the dilution of the association after adjustment for BMI and the relationship
between waist circumference and BMD in men and not in women.
There are several strength of our present study. First, this is a large prospective population
based study of 3,458 individuals, with comprehensive follow up of more than 6.7 years on aver-
age. We were also able to examine both cross-sectional and longitudinal the associations be-
tween MS, BMD and osteoporosis. Additionally, the present study had various indices of bone
outcomes available, including hip bone geometry parameters and fracture incidence. Moreover,
in contrast to other studies, we used the most recent definition of MS. Yet our study has some
limitations. We did not have measures of glucose control, such as HBA1C which could have
strengthened our results. Secondly, the subjects in this study were only caucasians. Ethnic dif-
ferences in the association between MS and/or its components and bone have been previously
reported. Thus, our findings may not be extended to non-caucasian groups.
In conclusion, MS is associated with higher BMD, increase instability and narrower bone,
which is mainly driven by elevated glucose levels. In men but not in women, higher FN-BMD
was mainly explained by body mass index and body fat distribution. We postulate that the
bone of MS individuals is not yet characterized by an accumulation of microcracks (cortical po-
rosity) that would reflect sustained impairment of bone structure, and therefore yet an in-
creased risk of fragility, as observed in diabetic individuals. These highlight the importance of
maintaining glycemic control in individuals with MS to pervert skeletal complications and pre-
serve bone health.
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